Long non-coding RNA CASC2 regulates osteoblasts matrix mineralization

Frontiers in Bioengineering and Biotechnology

Bioengineering and Biotechnology

Mário Adolfo Barbosa¹  Susana G. Santos¹  Jaime Freitas¹  Maria Inês Almeida²  Sara Reis Moura² 

[1] i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal;INEB—Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal;i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal;INEB—Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal;ICBAS—Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal;

关键词: long noncoding transcripts;    mesenchymal stem/stromal cells;    bone;    cell differentiation;    extracellular matrix;   

DOI  :  10.3389/fbioe.2023.1155596

 received in 2023-01-31, accepted in 2023-05-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

Long non-coding RNAs (lncRNAs) are master regulators of gene expression and have recently emerged as potential innovative therapeutic targets. The deregulation of lncRNA expression patterns has been associated with age-related and noncommunicable diseases in the bone tissue, including osteoporosis and tumors. However, the specific role of lncRNAs in physiological or pathological conditions in the bone tissue still needs to be further clarified, for their exploitation as therapeutic tools. In the present study, we evaluate the potential of the lncRNA CASC2 as a regulator of osteogenic differentiation and mineralization. Results show that CASC2 expression is decreased during osteogenic differentiation of human bone marrow-derived Mesenchymal Stem/Stromal cells (hMSCs). CASC2 knockdown, using small interfering RNA against CASC2 (siCASC2), increases the expression of the late osteogenic marker Bone Sialoprotein (BSP), but does not impact ALP staining level nor the expression of early osteogenic transcripts, including RUNX2 and OPG. Although siCASC2 does not impact hMSC proliferation nor apoptosis, it promotes the mineralization of hMSC cultured under osteogenic-inducing conditions, as shown by the increase of calcium deposits. Mass spectrometry-based proteomic analysis revealed that 89 proteins are regulated by CASC2 at late osteogenic stages, including proteins associated with bone diseases or anthropometric and musculoskeletal traits. Specifically, the Cartilage Oligomeric Matrix Protein (COMP) is highly enhanced by CASC2 knockdown at late stages of osteogenic differentiation, at both transcriptional and protein level. On the other hand, inhibition of COMP impairs osteoblasts mineralization as well as the expression of BSP. The results indicate that lncRNA CASC2 regulates late osteogenic differentiation and mineralization in hMSC via COMP and BSP. In conclusion, this study suggests that targeting lncRNA CASC2 could be a potential approach for modulating bone mineralization.

【 授权许可】

Unknown   
Copyright © 2023 Freitas, Moura, Barbosa, Santos and Almeida.